Description

1-(4-Oxo-1-Phenyl-1,3,8-Triazaspiro[4.5]Dec-8-Yl)Cyclohexanecarbonitrile is a high-purity, advanced pharmaceutical intermediate with a complex spirocyclic structure. This compound matters for its critical role in the synthesis of novel active pharmaceutical ingredients (APIs), particularly in central nervous system (CNS) and metabolic disorder research. Pharmaceutical manufacturers and advanced R&D laboratories need this precise chemical building block to develop next-generation therapeutic agents with improved efficacy and safety profiles.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel spirocyclic-based active pharmaceutical ingredients (APIs).
• CNS Drug Research: Used in the development of potential therapeutics for neurological and psychiatric disorders.
• Metabolic Disorder Therapeutics: Serves as a precursor in research for diabetes and obesity-related drug candidates.
• Medicinal Chemistry R&D: A valuable scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery.
• Contract Manufacturing (CMO): Supplied to contract manufacturing organizations for the production of clinical trial materials.
• Academic Research: Utilized in university and institutional labs for studying spirocyclic compound chemistry and bioactivity.

Basic Information

Product Name	1-(4-Oxo-1-Phenyl-1,3,8-Triazaspiro[4.5]Dec-8-Yl)Cyclohexanecarbonitrile
CAS No.	101564-19-6
Molecular Formula	C20H24N4O
Molecular Weight	336.44 g/mol
Synonyms	1-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)cyclohexanecarbonitrile; 8-(1-Cyano-1-cyclohexyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one; Cyclohexanecarbonitrile, 1-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)-; 1-Phenyl-8-(1-cyanocyclohexyl)-1,3,8-triazaspiro[4.5]decan-4-one; Spirocyclic nitrile intermediate; CAS 101564-19-6
EINECS	Contact for details

Quality Control

Our 1-(4-Oxo-1-Phenyl-1,3,8-Triazaspiro[4.5]Dec-8-Yl)Cyclohexanecarbonitrile is manufactured under strict quality management systems, ensuring batch-to-batch consistency suitable for pharmaceutical R&D and scale-up. All products undergo rigorous analytical testing, including HPLC, NMR, and MS, to verify identity and purity. Certificates of Analysis (COA) detailing all specifications are provided with each shipment. We adhere to cGMP principles where applicable to support our clients' regulatory compliance needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.